

NCT02416765 Raw comparison:

Summary:
CHIA has 14 criteria while your personal folder has 15 criteria
Total found criteria: 14/14
Total not Found: 0/14
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Males and females ≥ 18 years old                   │ Males and females ≥ 18 years old                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinical diagnosis of type 1 diabetes for at least │ Clinical diagnosis of type 1 diabetes for at least │
│ one year                                           │ one year                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The subject will have been on insulin pump therapy │ The subject will have been on insulin pump therapy │
│ for at least 3 months and currently using a fast   │ for at least 3 months and currently using a fast   │
│ actin insulin analog (Lispro Aspart or Guilisine)  │ actin insulin analog (Lispro Aspart or Guilisine)  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Last (less than 3 months) HbA1c ≤ 10%              │ Last (less than 3 months) HbA1c ≤ 10%              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently using carbohydrate counting as the meal  │ Currently using carbohydrate counting as the meal  │
│ insulin dose strategy                              │ insulin dose strategy                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant microvascular complications │ Clinically significant microvascular complications │
│ nephropathy (estimated glomerular filtration rate  │ nephropathy (estimated glomerular filtration rate  │
│ below 40 ml/min) neuropathy (especially diagnosed  │ below 40 ml/min) neuropathy (especially diagnosed  │
│ gastroparesis) or severe proliferative retinopathy │ gastroparesis) or severe proliferative retinopathy │
│ as judged by the investigator                      │ as judged by the investigator                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Recent (< 3 months) acute macrovascular event e g  │ Recent (\< 3 months) acute macrovascular event e g │
│ acute coronary syndrome or cardiac surgery         │ acute coronary syndrome or cardiac surgery         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing pregnancy                                  │ Ongoing pregnancy                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hypoglycemic episode within 1 month of      │ Severe hypoglycemic episode within 1 month of      │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Agents affecting gastric emptying (Motilium®       │ Agents affecting gastric emptying (Motilium®       │
│ Prandase® Victoza® Byetta® and Symlin®) as well as │ Prandase® Victoza® Byetta® and Symlin®) as well as │
│ oral anti-diabetic agents (Metformin SGLT-2        │ oral anti-diabetic agents (Metformin SGLT-2        │
│ inhibitors and DPP-4 inhibitors) if not at a       │ inhibitors and DPP-4 inhibitors) if not at a       │
│ stable dose for 3 months Otherwise these           │ stable dose for 3 months Otherwise these           │
│ medications are acceptable and will be kept stable │ medications are acceptable and will be kept stable │
│ during the entire protocol                         │ during the entire protocol                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Oral steroids unless patients present a low stable │ Oral steroids unless patients present a low stable │
│ dose (e g 10 mg or less of prednisone per day or   │ dose (e g 10 mg or less of prednisone per day or   │
│ physiological doses less than 35 mg/day of         │ physiological doses less than 35 mg/day of         │
│ hydrocortisone Cortef®) Inhale steroids at stable  │ hydrocortisone Cortef®) Inhale steroids at stable  │
│ dose in the last month are acceptable              │ dose in the last month are acceptable              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other serious medical illness likely to interfere  │ Other serious medical illness likely to interfere  │
│ with study participation or with the ability to    │ with study participation or with the ability to    │
│ complete the trial by the judgment of the          │ complete the trial by the judgment of the          │
│ investigator (e g unstable psychiatric condition)  │ investigator (e g unstable psychiatric condition)  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failure to comply with team's recommendations (e g │ Failure to comply with team's recommendations (e g │
│ not willing to change pump parameters follow       │ not willing to change pump parameters follow       │
│ algorithm's suggestions etc)                       │ algorithm's suggestions etc)                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Living or planned travel outside Montreal (> 1h of │ Living or planned travel outside Montreal (\> 1h   │
│ driving) area during closed-loop procedures        │ of driving) area during closed-loop procedures     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛